Antigen response enhancer

An antigen response enhancer using Euglena and β-1,3-glucan increases naive T cells and enhances immune markers to improve immune function and counteract aging-related immune decline.

JP2026105098APending Publication Date: 2026-06-25KOBELCO ECO SOLUTIONS CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2026071199
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-03
Filing Date
2026-04-23
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

As organisms age, the immune system declines due to an increase in senescent T cells and a decrease in naive T cells, leading to reduced antigen responsiveness, which compromises the immune defense mechanism.

Method used

An antigen response enhancer containing Euglena, paramylon, or β-1,3-glucan is developed to promote the increase in naive T cells, enhance CD28 expression, and increase other immune markers such as CD80, CD86, and HLA-DR in monocytes, thereby boosting the immune response.

Benefits of technology

The enhancer effectively increases the number and activity of naive T cells and regulatory T cells, enhances antigen presentation, and improves overall immune function, counteracting immunosenescence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026105098000002
    Figure 2026105098000002
  • Figure 2026105098000003
    Figure 2026105098000003
  • Figure 2026105098000004
    Figure 2026105098000004
Patent Text Reader

Abstract

To provide an antigen responsiveness enhancer. [Solution] From Euglena, paramylon, paramylon processed product, and β-1,3-glucan An antigen response enhancer containing at least one selected from the group.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Cosmetic or dermatological pharmaceutical composition containing Euglena extract

    JP2008526954A